Discover Great Companies Discover Great Clients
Popularity  5.6万   |   Followers  14   |   Likes  20   |   Feedback  15 Claim this company
No.214 Beijing City Popularity Ranking No.78 Haidian District No.1 Vaccines No.1 Food Additives No.1 Yi Bing Fang Kong No.1 Yu Fang Bao Jian No.1 Vaccines Technology No.1 Anti-corrosion Technology No.1 Ren Yong Yi Miao No.3 Biological Products No.4 Biotechnology Pharmaceuticals No.4 Gong Cheng Yan Jiu Center No.6 Pharmaceutical Technology No.6 Biopharmaceuticals 企业技术中心 创新型企业 自主创新示范企业 省部级科技进步奖 高新技术企业 发明专利 GMP认证
More

Company Overview

  • Nature: Joint Venture Size: 1000-4999 employees Founded: 25年
  • Industry: Pharmaceutical/Bioengineering
  • Full name: Beijing Sinovac Biotech Co., Ltd.。

Development Stage

  • Ranking: Ranked #214 in Beijing City by popularity Ranked #1 in Beijing Vaccines Company by popularity Ranked #1 in Beijing Food Additives Company by popularity Ranked #1 in Beijing Yi Bing Fang Kong Company by popularity Ranked #1 in Beijing Yu Fang Bao Jian Company by popularity
  • Honors: 2022中国500强 企业技术中心 创新型企业 According to algorithm
  • Salary: 49.5% of positions earn 10-20K, In 2026 vs last yeardecreased by 5%.。Master's salary: ¥18.9K.
  • R&D: "Biology/Pharmaceutical/Chemical/Environmental Protection" demand: 21.6%, "Medical & Health/Beauty & Healthcare": 11.8%, "Computer/Network/Technology": 9.8%。
  • Recruiting: In 2026 vs 2025grew by 50%. Demand for highly educated talent: Master's: 1.
  • Requirement: Education: 本科 leads with 82.6%. Experience: 不限 leads with 29.4%.
  • Region: Distributed across 1 regions, 北京: 98.6%, 大连: 1.4%.

About the Company

Beijing Sinovac Biotech Co., Ltd. is a high-tech biotechnology enterprise registered in 2001 in the Zhongguancun National Innovation Demonstration Zone, Beijing, by Sinovac Biotech Ltd., a Nasdaq-listed company (China Sinovac), with a registered capital of RMB 141.21 million. The company is one of the first batch of innovative enterprises in the Zhongguancun National Innovation Demonstration Zone, a key cultivated enterprise under Beijing's first batch of the "Ten-Hundred-Thousand" project and the "Beijing Biomedical Industry Leapfrog Development Project" (G20 Project), the Beijing Engineering Research Center for New Human Preventive Vaccines, and a Beijing Municipal Enterprise Technology Center.
With the mission of "providing vaccines to eliminate diseases for humanity," the company specializes in the research, development, production, and sales of human vaccines and related products, offering services for disease prevention and control in China and globally. Since its inception, the company launched the inactivated hepatitis A vaccine Healive®, filling a domestic gap, followed by the combined hepatitis A and B vaccine Bilive®, the pandemic influenza (H5N1) vaccine Panflu®, the first preservative-free split influenza vaccine Anflu®, and the H1N1 influenza vaccine Panflu.1®, as well as the Class 1 new biological product for prevention—the inactivated enterovirus type 71 vaccine Inlive®, a quadrivalent influenza vaccine, a 23-valent pneumococcal polysaccharide vaccine (PPV23), and the Sabin strain inactivated poliovirus vaccine (sIPV). Additionally, the company has developed the world's first SARS inactivated vaccine (completed Phase I clinical trials). At the end of 2017, Healive® obtained World Health Organization (WHO) prequalification. In June 2022, the sIPV also received WHO prequalification.
From isolating the hepatitis A virus TZ84 strain to resolving the crystal structures of hepatitis A and EV71, and from fighting SARS to controlling H1N1 influenza and hand, foot, and mouth disease, Sinovac staff have always been committed to innovation, driven by the health needs of the Party, the country, and the people. Throughout this process, Sinovac has undertaken over 40 national and provincial/ministerial science and technology projects, including those under the National Key Technology R&D Program, the 863 Program, the National Major New Drug Creation Program, and the Major Infectious Disease Prevention and Control Program. It has won 4 national science and technology awards and 4 provincial/ministerial awards. To date, it has applied for 77 national invention patents, with 49 authorized. Research findings have been published in over 60 SCI-indexed papers, many of which appeared in international academic journals such as the
New England Journal of Medicine, The Lancet, Nature, and Science.
The company mainly sells its vaccines in the Chinese market, while also continuously exploring international market opportunities. It has exported vaccines to dozens of countries and international organizations.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Sinovac Biotech How Fast Is Hiring Growing? (26 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Up 167%
  • 2024: Down 8%
  • 2023: Down 41%
  • 2022: Down 44%
Sinovac Biotech Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
Sinovac Biotech Campus Recruitment & Advanced Degree Talent Demand
Interns 3 Master's 1
Note: How fast is hiring at Beijing Sinovac Biotech Co., Ltd. growing? Sinovac Biotech2026: 180 openings (up 50%), 2025: 120 openings (up 167%), 2024: 45 openings (down 8%), 2023: 49 openings (down 41%), 2022: 83 openings (down 44%), 2021: 149 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Sinovac Biotech Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Up 46%
  • 2024: Up 30%
  • 2023: Down 44%
  • 2022: Down 22%
Sinovac Biotech Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at Beijing Sinovac Biotech Co., Ltd. growing? Sinovac BiotechMaster's recruitment over the years: 2025: 19 openings (up 46%), 2024: 13 openings (up 30%), 2023: 10 openings (down 44%), 2022: 18 openings (down 22%), 2021: 23 openings.

Sinovac Biotech R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at Beijing Sinovac Biotech Co., Ltd.? Based on an analysis of Sinovac Biotech's job postings over the past year, "Biology/Pharmaceutical/Chemical/Environmental Protection" demand: 21.6%, "Medical & Health/Beauty & Healthcare": 11.8%, "Computer/Network/Technology": 9.8%, "Other (R&D and Technical)": 7.8%, "Agriculture, Forestry and Fishery": 2%, "Mechanical/Instrumentation": 1.5%. For reference only.

Sinovac Biotech — What Are the Salaries Like? (204 records)

Manage
salary range: 3K - 50K, 49.5% of roles pay ¥10-20K
Note: salary statistics are based on 204 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Beijing Sinovac Biotech Co., Ltd.?Sinovac Biotech49.5% of positions earn 10-20K, Fresh graduate salary: ¥7.0K。Beijing salary ranking: #3426,生物/制药/化工/环保类 average salary ¥15.1K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of Sinovac Biotech

(More)
Are salaries high at Beijing Sinovac Biotech Co., Ltd.? We provide: BP, Quality, Intern, International Business Specialist, Business Development, Translator, HR, 临床, Portuguese Translator, HR Specialist, Analyst, Finance Specialist, Information, Quality Control, Senior Supervisor, Marketing, 检验, Public Affairs, Production Technician, Research Engineer. Click to view detailed salary analysis by job.

Sinovac Biotech — Fortune 500? (More)

Yes, ranked in 中国500强:

  • NO.109 2022中国500强 >

Sinovac Biotech honors, qualifications & industry associations

Job Category

  • 生物/制药/化工/环保类
    20.2% of total 20.2%
  • 经营管理类
    18.8% of total 18.8%
  • 市场/公关/媒介类
    16.5% of total 16.5%
  • 质量管理类
    15.6% of total 15.6%

Education

  • 本科
    82.6% of total 82.6%
  • 硕士
    9.6% of total 9.6%
  • 大专
    4.1% of total 4.1%
  • 不限
    3.7% of total 3.7%

Experience

  • 不限
    29.4% of total 29.4%
  • 3-5年
    27.5% of total 27.5%
  • 5-10年
    20.6% of total 20.6%
  • 1-3年
    20.2% of total 20.2%
View Detailed Analysis

What does Beijing Sinovac Biotech Co., Ltd. require? Who is Sinovac Biotech hiring? Sinovac Biotech recruitment: 生物/制药/化工/环保类占比最多占20.2%,其次是经营管理类占18.8%. What education can get in at Sinovac Biotech? 本科占比最多占82.6%,其次是硕士占9.6%. High education required at Sinovac Biotech? 硕士占9.6%. Work experience required at Sinovac Biotech? 不限占比最多占29.4%,其次是3-5年占27.5%. Where are the job locations at Sinovac Biotech? 北京占比最多占98.6%,其次是大连占1.4%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 14,121万(元)
Legal Representative: 尹卫东
Date Established:
Credit Code: 91110108600088085T
Registered Address: 北京市海淀区上地西路39号

Partners & Suppliers

采购新冠疫苗生产线设备 Source
供应商 制药企业客户
公司为其疫苗生产提供细胞培养基 Source
供应商 疫苗
公司委托其进行干扰素制剂的加工生产。 Source
合作客户 药品委托生产
为科兴新冠灭活疫苗提供培养基 Source
供应商 疫苗
科兴(大连)作为科兴控股的疫苗生产基地,向北京科兴生物制品有限公司供应新冠疫苗原液,用于最终成品的灌装和生产。 Source
供应商 疫苗原液供应

People who follow Sinovac Biotech also follow

Sinovac Biotech Competitors (Similar Companies)

“Engaged in the research and development as well as technical services ”
“Research and development of recombinant protein drugs and microecologi”
“Large pharmaceutical and health industry group”
“A pharmaceutical enterprise with over 70 years of glorious history”
生物制品 化学制药 医疗器械 生产
“Dedicated to the research and development of molecularly targeted drug”
“Large pharmaceutical group”
“Adhering to the corporate culture of science and excellence, committed”
制药/药业 生命科学 生物制品 生物制药
“Improving public health”
“Helping partners successfully develop new drugs, reducing R&D costs an”
“R&D, production and commercialization of high-quality human vaccines”
“药物开发服务商”
“Pharmaceutical preparations and medical devices”
生物制品 疫苗 疫苗研发 狂犬疫苗

Discover Great Companies, Discover Great Clients

北京公司名录 北京“Haidian District”公司名录 北京“疫苗”公司名录 北京“医药”公司名录 北京“生物制品”公司名录 北京“生物医药”公司名录 北京“人用疫苗”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates